Radiochemical, Computational, and Spectroscopic Evaluation of High-Denticity Desferrioxamine Derivatives DFO2 and DFO2p toward an Ideal Zirconium-89 Chelate Platform.
暂无分享,去创建一个
Elaheh Khozeimeh Sarbisheh | I. Pickering | K. Summers | J. Cotelesage | E. Price | Amanda Zimmerling | Graham N George | A. Salih | A. K. Salih | A. Zimmerling
[1] E. Price,et al. Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry. , 2022, Inorganic chemistry.
[2] A. Rogachev,et al. Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability , 2022, ACS omega.
[3] G. Fricker,et al. Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? , 2022, Pharmaceutics.
[4] Dijie Liu,et al. Synthesis and Evaluation of Diaza-Crown Ether-Backboned Chelator Containing Hydroxamate Groups for Zr-89 Chelation Chemistry. , 2022, Bioorganic & medicinal chemistry letters.
[5] F. Bénard,et al. Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET. , 2022, Journal of inorganic biochemistry.
[6] G. Fricker,et al. Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability , 2021, Cancers.
[7] H. Stephan,et al. [nat/89Zr][Zr(pypa)]: Thermodynamically Stable and Kinetically Inert Binary Nonadentate Complex for Radiopharmaceutical Applications. , 2021, Inorganic chemistry.
[8] M. Schwaiger,et al. A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging , 2021, Molecules.
[9] G. Gasser,et al. The Race for Hydroxamate-Based Zirconium-89 Chelators , 2021, Cancers.
[10] A. Baldi,et al. Thermodynamic Stability and Speciation of Ga(III) and Zr(IV) Complexes with High-Denticity Hydroxamate Chelators , 2021, Inorganic chemistry.
[11] A. Windhorst,et al. Comparison of analytical methods for antibody conjugates with application in nuclear imaging - Report from the trenches. , 2021, Nuclear medicine and biology.
[12] R. Boellaard,et al. Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer , 2021, The Journal of Nuclear Medicine.
[13] F. Rösch,et al. Development and in vitro evaluation of new bifunctional 89Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications. , 2021, Nuclear medicine and biology.
[14] P. Choyke,et al. In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab , 2021, Cancer biotherapy & radiopharmaceuticals.
[15] H. Fonge,et al. 89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo , 2021, Cancers.
[16] R. Boellaard,et al. The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals , 2020, The Journal of Nuclear Medicine.
[17] Elaheh Khozeimeh Sarbisheh,et al. Structural Characterization of the Solution Chemistry of Zirconium(IV) Desferrioxamine: A Coordination Sphere Completed by Hydroxides. , 2020, Inorganic chemistry.
[18] G. V. van Dongen,et al. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[19] Elaheh Khozeimeh Sarbisheh,et al. A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89. , 2020, Inorganic chemistry.
[20] H. Fonge,et al. Production and Semi-Automated Processing of 89Zr Using a Commercially Available TRASIS MiniAiO Module , 2020, Molecules.
[21] B. Guérin,et al. Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator , 2020, ACS omega.
[22] Jason S. Lewis,et al. A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET. , 2020, Bioconjugate chemistry.
[23] J. Holland. Predicting the Thermodynamic Stability of Zirconium Radiotracers. , 2020, Inorganic chemistry.
[24] F. Bénard,et al. Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular 89Zr-THPN-Conjugates. , 2019, Inorganic chemistry.
[25] D. Sokaras,et al. X-ray Absorption Spectroscopy Investigations of Copper(II) Coordination in the Human Amyloid β Peptide. , 2019, Inorganic chemistry.
[26] W. Oyen,et al. Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. , 2018, European urology.
[27] R. Reilly,et al. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab. , 2018, Molecular pharmaceutics.
[28] Jason S. Lewis,et al. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model , 2018, Molecular Imaging and Biology.
[29] F. Bénard,et al. Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89Zr for imaging with positron emission tomography. , 2018, Bioorganic & medicinal chemistry letters.
[30] T. Wadas,et al. Recent Advances in Zirconium-89 Chelator Development , 2018, Molecules.
[31] B. Wängler,et al. Rational Design, Development, and Stability Assessment of a Macrocyclic Four‐Hydroxamate‐Bearing Bifunctional Chelating Agent for 89Zr , 2017, ChemMedChem.
[32] Justin J. Wilson,et al. Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development. , 2017, Molecular pharmaceutics.
[33] Lars Konermann,et al. Addressing a Common Misconception: Ammonium Acetate as Neutral pH “Buffer” for Native Electrospray Mass Spectrometry , 2017, Journal of The American Society for Mass Spectrometry.
[34] T. Aweda,et al. Production of Zr-89 using sputtered yttrium coin targets 89Zr using sputtered yttrium coin targets. , 2017, Nuclear medicine and biology.
[35] Jason S. Lewis,et al. 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection , 2017, The Journal of Nuclear Medicine.
[36] R. Codd,et al. Octadentate Zirconium(IV)-Loaded Macrocycles with Varied Stoichiometry Assembled From Hydroxamic Acid Monomers using Metal-Templated Synthesis. , 2017, Inorganic chemistry.
[37] Danny F. Martinez,et al. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake , 2016, The Journal of Nuclear Medicine.
[38] G. V. van Dongen,et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[39] Marc C. Huisman,et al. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? , 2016, Front. Pharmacol..
[40] Nathaniel T Kenton,et al. Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging. , 2016, ChemPlusChem.
[41] Simon-Peter Williams,et al. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice , 2016, Theranostics.
[42] Jason S. Lewis,et al. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. , 2015, Bioconjugate chemistry.
[43] C. Decristoforo,et al. Novel Bifunctional Cyclic Chelator for 89Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates , 2015, Molecular pharmaceutics.
[44] Jason S. Lewis,et al. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. , 2015, Journal of visualized experiments : JoVE.
[45] Jason S. Lewis,et al. What a Difference a Carbon Makes: H4octapa vs H4C3octapa, Ligands for In-111 and Lu-177 Radiochemistry , 2014, Inorganic chemistry.
[46] Y. Lee,et al. Propylene cross-bridged macrocyclic bifunctional chelator: a new design for facile bioconjugation and robust (64)Cu complex stability. , 2014, Journal of medicinal chemistry.
[47] Jason S. Lewis,et al. Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO) , 2014, Journal of medicinal chemistry.
[48] M. Brechbiel,et al. Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). , 2014, Chemistry.
[49] Jason S. Lewis,et al. Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology , 2013, The Journal of Nuclear Medicine.
[50] Donald G. Truhlar,et al. M11-L: A Local Density Functional That Provides Improved Accuracy for Electronic Structure Calculations in Chemistry and Physics , 2012 .
[51] T. Nayak,et al. PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1–Targeted 89Zr-Labeled Panitumumab , 2012, The Journal of Nuclear Medicine.
[52] R. Weissleder,et al. Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click Chemistry , 2011, Bioconjugate chemistry.
[53] D. Abou,et al. In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.
[54] Yin Zhang,et al. PET tracers based on Zirconium-89. , 2011, Current radiopharmaceuticals.
[55] S. Larson,et al. 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo , 2010, The Journal of Nuclear Medicine.
[56] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[57] C. Saturnino,et al. Chemical and biological properties of toxic metals and use of chelating agents for the pharmacological treatment of metal poisoning , 2010, Archives of Toxicology.
[58] Valerie A Longo,et al. Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab , 2010, PloS one.
[59] Jason S. Lewis,et al. Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.
[60] Johan R de Jong,et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.
[61] O. Visser,et al. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[62] B. Delley. From molecules to solids with the DMol3 approach , 2000 .
[63] R. Prince,et al. The Molybdenum Site of Sulfite Oxidase: A Comparison of Wild-Type and the Cysteine 207 to Serine Mutant Using X-ray Absorption Spectroscopy , 1996 .
[64] Andreas Klamt,et al. Incorporation of solvent effects into density functional calculations of molecular energies and geometries , 1995 .
[65] B. Delley. An all‐electron numerical method for solving the local density functional for polyatomic molecules , 1990 .
[66] D. Rosenthal,et al. Treatment of iron overload in adults with continuous parenteral desferrioxamine. , 1977, The American journal of medicine.